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Abstract
Background: The outcome of rheumatoid arthritis (RA) should be determined early. Rapid radiological progression
(RRP) is > or = 5 units increase according to the van der Heijde-Sharp score within a year. The risk of RRP can be
estimated by a matrix model using non-radiographic indicators, such as C-reactive protein (CRP), rheumatoid factor
(RF) and swollen joint count (SJC).
Patients and methods: A non-interventional, cross-sectional, retrospective study was conducted in eleven
Hungarian arthritis centres. We assessed RRP risk in biologic-naïve RA patients with the prevalence of high RRP risk
as primary endpoint. RRP was calculated according to this matrix model. As a secondary endpoint, we compared
RRP in methotrexate (MTX) responders vs non-responders.
Results: We analyzed data from 1356 patients. Mean CRP was 17.7 mg/l, RF was 139.3 IU/ml, mean 28-joint disease
activity score (DAS28) was 5.00 and mean SJC was 6.56. Altogether 18.2% of patients had high risk (≥40%) of RRP.
RA patients with high RRP risk of RRP (n = 247) had significantly lower age compared to those with RRP < 40% (n =
1109). MTX non-response (OR: 16.84), male gender (OR: 1.67), erosions at baseline (OR: 1.50) and ACPA seropositivity
(OR: 2.18) were independent predictors of high-risk RRP. Male gender (OR: 5.20), ACPA seropositivity (OR: 4.67) and
erosions (OR: 7.98) were independent predictors of high RRP risk in MTX responders.
Conclusions: In this Hungarian study, high RRP risk occurred in 18% of RA patients. These patients differ from
others in various parameters. RRP was associated with non-response to MTX.
Keywords: Rheumatoid arthritis, Anti-TNF therapy, Infliximab, Biological therapy, Outcome, Rapid radiographic
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Key points
– In Hungary, one-fifth of RA patients has rapid radio-
graphic progression.
– MTX non-response, male gender and ACPA positivity
were independent predictors of high-risk rapid radio-
graphic progression.
Introduction
Radiographic damage may be one of the most important
outcomes of rheumatoid arthritis (RA). Therefore, we
should identify patients at high risk for rapid radio-
graphic progression (RRP) early, which should influence
our treatment strategy. In such patients, effective therapy
may reduce the odds of progression [1, 2]. Early, inten-
sive treatment may slow down the rate of radiographic
progression [1–3]. Various clinical and biological markers
have been identified as baseline risk factors for radio-
graphic progression. Optimally, the combination of mul-
tiple markers may improve the value of prediction [3].
Recent recommendations for the management of rheuma-
toid arthritis (eg. EULAR, Hungarian National Guideline)
[1, 2, 4] introduce the importance of prognostic markers
in treatment decisions in RA referring to the matrix risk
model developed by Vastesaeger et al. [3]. These recom-
mendations also suggest the early introduction of biologic
therapy for patients with high risk of RRP [1, 2, 4].
In order to identify the need for earlier use of biologic
treatment in the everyday clinical practice, it is crucial to
estimate, which patients who would benefit the most
from early aggressive therapy. The matrix risk model de-
veloped by Vastesaeger et al. [3] is an evidence-based,
simple to use tool to assess the risk of RRP for patients
with a specific combination of easily accessible variables.
This model has been used in real-life on a community-
based sample of patients with active RA naïve to biologic
treatment. In a single center retrospective study in
Hungary 100 RA patients were assessed [5]. Altogether
21% of consecutive patients with active RA had a high
(≥40%) risk of RRP (vdHSS ≥5/year), and methotrexate
(MTX) responsiveness was a key parameter in determin-
ing the RRP risk calculation [5]. Durnez et al. [6] vali-
dated a matrix model in their observational early RA
cohort that was conceived based on data from the ASPI
RE early RA trial. In this, as well as other studies, pa-
tients with longer duration of RA had lower RRP risk [3,
5, 7]. In addition, predictors of RRP based on other pub-
lished matrix models are presence of anti-citrullinated
protein antibodies (ACPA), baseline erosions and
cigarette smoking [3, 5]. In the therapeutic guidelines
the Hungarian Ministry of Health endorsed the use of
the matrix prediction models in the therapeutic deci-
sions regarding the initiation of biologic therapies [4].
Certainly, there have been other models that estimated
RRP. For example, in various studies, 3-month DAS
[8], anti-neutrophil cytoplasmic antibodies [9], various
cartilage and proteoglycan turnover biomarkers [10],
matrix metalloproteinases [11, 12], some genetic
markers including tumor necrosis factor α (TNF-α)
gene polymorphisms [11] have been suggested as pre-
dictors of RRP. Moreover, early MRI bone edema [13]
and first-year radiographic progression determined
further progression in early RA [14]. With respect to
matrix-based risk models, Visser et al. [15] used auto-
antibodies, CRP, erosion score and treatment group in
the BeSt study to determine RRP. This model was able
to find differences in RRP in the four arms of the
study [15]. Very recently, Vanier et al. [16] presented
an updated matrix model by pooling individual data of
DMARD-naïve active, early RA patients from numer-
ous databases. Four parameters, such as RF positivity,
presence of at least one erosion at baseline, CRP and
SJC were retained [16]. On the other hand, there have
been studies criticizing the applicability of these
matrices in daily clinical practice. Lillegraven et al.
[17] compared three of these models including two
matrix-based models described above [3, 15]. This
study, which also included biologic-treated patients,
found that these models may have limited ability to
predict RRP in early RA [17]. De Cock et al. [18]
tested six matrices in 74 early RA patients with X-rays
of hands and feet at baseline. They did not find these
matrices fully reliable in RRP prediction in the daily
practice [18].
Our objective was to determine the risk of RRP according
to the matrix risk model developed by Vastesaeger et al. [3]
among Hungarian RA patients as a joint effort of national
arthritis centers. Although the original matrix model has
been developed for the use in clinical studies to determine
treatment efficacy [3], we wished to apply this model to se-
lect candidates for biological therapy among biologic-naïve
patients. This was a non-interventional, cross-sectional,
retrospective, population-based, nationwide survey based
on hospital record data. This was a theoretical prediction as
prospective follow-up of radiographic progression was not
performed.
Patients and methods
Brief description of the matrix risk model
In the model of Vastesaeger et al. [3], RRP was defined
as a threshold change in modified Sharp/van der Heijde
score (SHS) of > or = 5 U/year. The developed and vali-
dated matrix risk model enables to determined RRP
without actual radiographs based on three simple vari-
ables. In this model, the 28 swollen joint count (SJC), RF
and CRP levels were used as trichotomous variables.
These three variables weighed equally.
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Sample size calculation and patient selection process
We applied the precision-based sample size calculation
with the following formula to calculate the minimum sam-
ple size: π (1-π)/e2, where π is the expected proportion, e
is the required size of standard error. Precision is defined
as the ± range around the estimated proportion, and was
calculated as ±1.96 × e [19]. Calculating with π = 0.2 as the
expected proportion and ± 0.02 as the required precision,
the minimum required sample size was 1537. Assuming
as the estimated proportion of patients with incomplete
data will be 15%, the adjusted minimum sample size cal-
culated was 1537/0.85, which equals 1808 patients. This
was the number of patients required for the estimation
with the specified precision of ±0.02 (data not shown).
A multi-stage sampling method was applied to ensure
equal probability of selection of target patients. In order
to obtain a population-based sample, each of the 20 re-
gional rheumatology centers evenly distributed through-
out Hungary (1st-stage sampling units) were invited to
participate in the study. The number of cases per center
(n) was allocated according to the number of treated RA
patients in each center at the time of the start of the
study. Investigators then collected data on patients up to
the allocated sample size (n), thus ensuring sampling
probability proportional to size of the 1st-stage sampling
units (i.e., the 20 rheumatology centers).
Random selection of patients (2nd-stage sampling
units) was then performed to avoid any selection bias.
The list of all currently treated RA patients (sampling
frame) was created in each center. The allocated number
of patients was selected from the sampling frame with
simple random sampling (with tables of random num-
bers) in order to each patient having the same chance of
being chosen [20].
Based on these calculations, 1843 patients were con-
secutively chosen for data analysis (Fig. 1). The only in-
clusion criterion was the diagnosis of RA. There were no
exclusion criteria except for age ≤ 16 years (definition of
juvenile arthritis).
Data capture process
Patient data from the last visit that occurred right before
the date of patient selection were collected. For those
already on biologic therapy, the last data before initiation
of biologics were retrospectively recorded. Thus, only
data obtained from biologic-naïve patients were evalu-
ated. We used clinical data obtained from hospital re-
cords and also assess radiographs at baseline for the
presence or absence of erosions.
Standardized electronic spreadsheed (Microsoft Excel)
was used to capture the data. The following data were
collected based on hospital records:
– age
– gender
– duration of RA
– history of DMARD use (MTX and others; current/
past/never use)
– MTX response (responder/non-responder)
– SJC, CRP and RF levels (for calculation of the
matrix-based RRP risk)
– anti-citrullinated protein antibody (ACPA) status
(positive/negative)
– DAS28 activity score
– presence of baseline erosions on radiographs at
baseline (yes/no)
– cigarette smoking (current/past/never)
Fig. 1 Flowchart of the study
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For determining RRP, we used the traditional three
variables, SJC, RF and RF, as determined by Vastesaeger
et al. [3]. However, we added a few binary variables de-
scribed above in order to look for further denominators.
Objectives
The primary objective was to estimate the prevalence of
high (≥40%) risk of RRP in a community-based sample
of RA patients, naïve to biologic treatment presenting at
rheumatology departments. Active disease was defined
as DAS28 ≥ 5.1, which is the threshold for the use of bio-
logics in Hungary.
The secondary objectives were:
– to assess the difference in the prevalence of high
RRP risk in RA patients classified MTX-non-
responders versus MTX-responders (MTX non-
responders are patients with DAS28 > 5.1 despite
MTX treatment for at least 6 months in stable
doses);
– to assess the multivariate association of patient
characteristics with high RRP risk (independent of
the parameters used in matrix model).
Statistical analysis
The calculation of sample size is described above. MS
Excel was used to record, summarize and clean the data.
Statistical analyses were performed with IBM SPSS 20
program. Continuous variables were described by mean
and standard deviation, the distribution was described
with number of cases and percentage. Distribution was
analyzed with Kolmogorov-Smirnov test. Between group
difference was analyzed with Mann-Whitney test and
Chi2-test. Independent predictive factors were identified
applying univariable and multivariable regression ana-
lyses. We considered correlations to be significant in
case of a p-value less than 0.05.
Results
Data collection
Initially 1843 consecutive subjects were recruited. Four
subjects were excluded at the beginning due to age ≤ 16
years, 222 patients because of missing DAS28 scores and
261 patients due to missing data necessary for the calcu-
lation of RRP. Thus, in the end, data from 1356 RA pa-
tients could be included in the analysis. There were no
missing data in these 1356 patients (Fig. 1). The demo-
graphic and clinical data of these patients are seen in
Table 1. The mean age of the patients were 55.5 ± 13.3
years (range: 17–89) and the mean disease duration was
8.4 ± 8.8 years (range: 0–62). Altogether 1148 patients
(85%) were women. MTX-non-responders were cur-
rently taking MTX +DAS28 > 5.1.
Associations of various parameters with the risk RRP
First, the risk of RRP was calculated in all 1356 RA pa-
tients according to the matrix model [3]. The risk of
40% was the cutoff between high- and low-risk patients.
Altogether 247 patients exerted RRP risk ≥40% (18.2%)
and 1109 patients had low risk (81.8%) (Table 1).
Among continuous variables other than those used for
calculation of RRP risk, RA patients with the risk of
RRP ≥ 40% (n = 247) had significantly lower age than
those with RRP < 40% (n = 1109) (53.33 ± 12.31 vs
56.02 ± 13.50 years; p = 0.001) (Fig. 2). These two patient
groups did not show statistically significant difference in
disease duration (7.89 ± 9.31 vs 8.56 ± 8.70 years, respect-
ively; p = 0.104) (Fig. 2).
Binary variables included gender, ACPA status, base-
line presence of erosions on radiographs, current smok-
ing and MTX response status. With respect to binary
variables, the risk of RRP ≥ 40% was significantly associ-
ated with non-response to MTX (OR: 17.82), male gen-
der (OR: 1.53), ACPA positivity (OR: 2.11), the presence
of erosions (OR: 1.37) and current smoking (OR: 1.66)
(Table 2). Multivariable logistic regression analysis re-
vealed that MTX non-response (OR: 16.84), male gender
(OR: 1.67), erosions at baseline (OR: 1.50) and ACPA
positivity (OR: 2.18) were independent predictors of
high-risk RRP (≥40%) (Table 3).
Factors associated with non-response to MTX
As non-responsiveness to MTX may exert the far closest
association with high risk of RRP, we performed a
Table 1 Clinical and demographic data of the analyzed patients
(n = 1356)
Age (years) 55.5 ± 13.3
Female gender (%) 85
Disease duration (years) 8.4 ± 8.8
RF positivity (%) 76
RF absolute level (IU/ml) 139.3 ± 196.4
ACPA positivity (%) 72
CRP level (mg/l) 17.7 ± 23.8
DAS28 score 5.00 ± 1.59
Swollen joint count (n) 6.56 ± 5.44
Current MTX therapy (%) 64
MTX therapy ever (%) 92
MTX non-responder (%) 51
current csDMARD therapy (other than MTX) (%) 35
csDMARD therapy ever (other than MTX) (%) 76
Presence of erosions (%) 61
Current smoker (%) 26
Risk of RRP (%) 26.8 ± 13.7
Risk of RRP ≥ 40% (%) (primary endpoint) 18,2
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detailed analysis of factors significantly associated with
MTX response.
Among the 1356 analysed cases, we identified 691
MTX non-responders (51%) according to the definition
described above. As presented in Table 4, MTX non-
responders exerted significantly lower age (p < 0.001),
higher RF levels (p = 0.002), CRP levels (p < 0.001),
DAS28 score (p < 0.001) and SJC (p < 0.001) than re-
sponders. Also more MTX non-responders had erosions
(p = 0.033) and had been currently smoking (p = 0.03) at
the time of the study as compared to responders. Finally,
the mean risk of RRP was also significantly higher in
MTX non-responders (37.8 ± 6.6%) compared to
responders (15.3 ± 8.9%) (p < 0.001). On the other hand,
the calculated risk of RRP was not different between
MTX non-responders and responders. The risk of RRP
was rather low in both patient subsets (6.5 ± 4.2% and
5.8 ± 2.0%, respectively) (Table 4).
MTX non-responsive and responsive patient subsets
were also analysed separately with respect to the risk of
RRP and associated factors. Among continuous vari-
ables, neither age nor disease duration was different be-
tween the RRP ≥ 40% and RRP < 40% subsets within the
MTX non-responder group (data not shown). With re-
spect to univariable regression analysis of binary param-
eters in MTX non-responders, high risk of RRP was
Fig. 2 Associations of rapid radiographic progression (RRP≥ 40%) with age and disease duration
Table 2 Association of binary variables with risk of RRP in RA patients
RRP ≥ 40% RRP < 40% p Odds Ratio 95% CI
MTX-response (n = 1356):
Non-responders 229 (93%) 462 (42%) < 0.001 17.820 10.87–29.21
Responders 18 (7%) 647 (58%)
Gender (n = 1356):
male 50 (20%) 158 (14%) 0.018 1.527 1.073–2.174
female 197 (80%) 951 (86%)
ACPA status (n = 1221):
positive 186 (83%) 697 (70%) < 0.001 2.107 1.449–3.063
negative 38 (17%) 300 (30%)
Presence of erosions (n = 1204):
yes 159 (70%) 612 (63%) 0.046 1.371 1.004–1.870
no 69 (30%) 364 (37%)
Current smoking (n = 1034):
yes 70 (34%) 195 (24%) 0.003 1.656 1.191–2.303
no 137 (66%) 632 (76%)
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significantly associated with ACPA positivity (OR: 1.96)
and current smoking (OR: 1.56), but not with gender or
the presence of erosions (Table 5). Multivariable logistic
regression analysis revealed that ACPA positivity (OR:
1.925) was independent predictor of RRP risk ≥40% in
the MTX non-responder subset (Table 3).
Similarly, in MTX responders (n = 665), neither age nor
disease duration was different between the RRP ≥ 40%
(n = 18) and RRP < 40% (n = 647) subsets (data not
shown). Among the binary variables, high risk of RRP was
significantly associated with male gender (OR: 3.98), but
not with ACPA status, the presence of erosions or current
smoking as determined by p values and confidence inter-
vals (Table 6). However, multivariable logistic regression
analysis confirmed that male gender (OR: 5.20), ACPA
positivity (OR: 4.57) and the presence of erosions (OR:
7.98) were independent predictors of high RRP risk in the
MTX responder subpopulation (Table 3).
Discussion
This was the very first study that assessed the risk of RRP in
a Hungarian multicentre cohort of RA patients in real-life
setting. We found that 18.2% of RA patients exerted RRP
risk ≥40% based on a model using 3 variables as input pa-
rameters. This proportion with high risk of radiographic de-
terioration and joint damage can be considered significant.
In the analysed population, high risk of RRP was signifi-
cantly associated with lower male gender, ACPA positivity,
the presence of erosions and non-response to MTX. About
half of the analysed patients were MTX non-responders. In
MTX non-responders, RRP was significantly associated with
ACPA positivity, while male gender, ACPA positivity and
baseline erosions predicted RRP in MTX responders.
Ours was a biologic-naïve cohort of patients with estab-
lished RA, which only theoretically assessed the risk of
RRP not applying prospective evaluation of radiographic
progression. There have been other similar studies using
Table 3 Independent predictive factors for high-risk (≥40%) of RRP
Patient population Parameters Odds Ratio 95% CI p
All patients (n = 1356) MTX non-response 16.843 9.348–30.350 < 0.001
Male gender 1.673 1.030–2.717 0.038
ACPA positivity 2.180 1.366–3.480 0.001
MTX non-responders (n = 691) ACPA positivity 1.925 1.186–3.124 0.008
MTX responders (n = 665) Male gender 5.202 1.658–16.323 0.005
Presence of erosions 7.984 1.019–62.529 0.048
Table 4 Comparison of clinical and demographic data in MTX non-responders vs responders (n = 1356)
Parameter MTX non-responders (n = 691) MTX responders (n = 665) p
Age (years) 52.99 ± 12.15 58.16 ± 13.98 < 0.001
Female gender (%) 84 86 0.365
Disease duration (years) 8.17 ± 8.73 8.72 ± 8.92 0.292
RF positivity (%) 76 75 0.442
RF absolute level (IU/ml) 153.55 ± 203.52 123.89 ± 187.21 0.002
ACPA positivity (%) 72 70 0.139
CRP level (mg/l) 21.24 ± 25.73 14.00 ± 21.01 < 0.001
DAS28 score 5.99 ± 0.68 3.98 ± 1.61 < 0.001
Swollen joint count (n) 8.87 ± 4.98 4.01 ± 4.74 < 0.001
Current MTX therapy (%) 83 45 < 0.001
MTX therapy ever (%) 96 89 < 0.001
current csDMARD therapy (other than MTX) (%) 44 25 < 0.001
csDMARD therapy ever (other than MTX) (%) 82 71 < 0.001
Presence of erosions (%) 67 61 0.033
Current smoker (%) 29 23 0.030
Risk of RRP (%) 37.82 ± 6.64 15.25 ± 8.90 < 0.001
Risk of RRP – if switched to (infliximab (%) 6.54 ± 4.18 5.84 ± 2.00 0.408
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matrix-based prediction models, however, some of them
had different study design. After the introduction of the
model introduced by Vastesaeger et al. [3] also utilized by
us, Durnez et al. [6] validated the same matrix in their ob-
servational cohort based on the ASPIRE early RA trial by
also using radiographs. The model was useful to deter-
mine the predictive value of different treatment strategies
in early RA. Visser et al. [15] applied a slightly different
model by using autoantibodies, CRP, erosion score and
treatment group as predictors in the BeSt study to deter-
mine RRP. This model included the evaluation of radio-
graphs and was able to find differences in RRP between
the four treatment strategies applied in the BeSt study
[15]. Vanier et al. [16] have recently developed an updated
matrix model, where, in addition to RF positivity, SJC and
CRP, baseline erosions were also used as predictors. Data
were pooled from numerous large early RA cohorts in-
cluding registries and clinical trials. This model could de-
termine RRP probability with high precision. Although the
matrix had moderate sensitivity and specificity, the
authors found it useful for daily practice [16]. In contrast,
when Lillegraven et al. [17] compared three matrix-based
models including the one applied in our present study,
they found that these models may have limited predictive
value for RRP [17]. However, that study, in contrast to
ours, has been performed in patients with early and not
established RA and the study of Lillegraven at al [17] also
included patients already receiving biologics. De Cock
et al. [18] did not find these matrices reliable in the daily
clinical practice. Yet, the majority of studies, similarly to
ours, found matrix-based predictive models useful to sim-
ply predict RRP in the clinic.
We analyzed the risk of RRP in context with the pres-
ence of absence of baseline erosions. It may be consid-
ered strange to use erosions to predict further
radiographic progression, however, as mentioned above,
others have also used baseline erosions in their predict-
ive models [14, 16].
In conclusion, this is the first biologic-naïve Hungarian
RA cohort that assessed the risk of RRP. In this study,
Table 5 Association of binary variables with risk of RRP in MTX non-responders (n = 691)
RRP ≥ 40% (n = 229) RRP < 40% (n = 462) p Odds Ratio 95% CI
Gender
male 43 (16%) 69 (17%) 0.197 1.318 0.471–1.099
female 186 (84%) 393 (83%)
ACPA status:
positive 171 (82%) 307 (70%) 0.001 1.957 1.298–2.950
negative 37 (18%) 130 (30%)
Presence of erosions:
yes 145 (69%) 271 (66%) 0.485 1.135 0.795–1.619
no 66 (31%) 140 (34%)
Current smoking:
yes 66 (34%) 81 (25%) 0.025 1.558 1.055–2.302
no 126 (66%) 241 (75%)
Table 6 Association of binary variables with risk of RRP in MTX responders (n = 665)
RRP > =40% (n = 18) RRP < 40% (n = 647) p Odds Ratio 95% CI
Gender
male 7 (40%) 89 (14%) 0.009 3.984 1.506–10.526
female 11 (60%) 558 (86%)
ACPA status:
positive 15 (94%) 390 (70%) 0.049 6.538 0.857–49.896
negative 1 (6%) 170 (30%)
Presence of erosions
yes 14 (82%) 341 (60%) 0.067 3.065 0.871–10.789
no 3 (18%) 224 (40%)
Current smoking:
yes 4 (27%) 114 (23%) 0.755 1.247 0.390–3.991
no 11 (73%) 391 (77%)
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high RRP risk was determined in 18% of the patients.
These patients differ from others in various clinical and
serological parameters. RRP has also been associated
with non-response to MTX. Our data, together with
other studies, suggest that such models may be useful to
predict radiographic progression in the daily practice.
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